A new and higher dose of obesity drug Wegovy has joined Novo Nordisk’s semaglutide portfolio, giving patients and doctors more options for treatment.

Dr. Reddy’s launches oral semaglutide tablets in India, expanding its GLP-1 therapy portfolio for diabetes treatment.

A new and higher dose of obesity drug Wegovy has joined Novo Nordisk’s semaglutide portfolio, giving patients and doctors more options for treatment.